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A novel approach to pancreatic cancer biomarker discovery has been developed, which employs a
stable isotope labeled proteome (SILAP) standard coupled with extensive multidimensional separation
coupled with tandem mass spectrometry (MS/MS). Secreted proteins from CAPAN-2 human pancreatic
cancer derived cells were collected after conducting stable isotope labeling by amino acids in cell culture
(SILAC). The resulting SILAP standard contained <0.5% of individual unlabeled proteins. Pooled sera
from patients with early stage pancreatic cancer or controls were prepared, and an equal amount of
the SILAP standard was added to each sample. Proteins were separated by isoelectric focusing (IEF)
prior to two-dimensional liquid chromatography (2D-LC)–MS/MS analysis. A total of 1065 proteins were
identiﬁed of which 121 proteins were present at 1.5-fold or greater concentrations in the sera of patients
with pancreatic cancer. ELISA validation of these ﬁndings was successfully performed for two proteins,
ICAM-1 and BCAM. Results of these studies have provided proof of principle that a SILAP standard
derived from the CAPAN-2 secreted proteome can be used in combination with extensive multidimen-
sional LC-MS/MS for the identiﬁcation and relative quantitation of potential biomarkers of pancreatic
cancer. This technique allows for the detection of low-abundance proteins, and focuses only on
biologically relevant proteins derived from pancreatic cancer cells.
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Introduction
Pancreatic cancer is the fourth most common cause of
cancer-related mortality in the United States.
1 The ﬁve-year
survival rate is the lowest among all cancers, with estimates
ranging from 0.4 to 4%. In 2007, an estimated 37 170 new cases
of pancreatic were diagnosed, and an estimated 33 370 patients
died as a result of their disease.
2 No effective screening
biomarker exists for the early detection of pancreatic cancer.
Carbohydrate antigen (CA) 19-9 is the most commonly used
protein tumor marker for pancreatic cancer, however its use
is largely limited to following the course of disease.
3,4 This is
primarily because CA 19-9 can be expressed in benign condi-
tions such as cholangitis and chronic pancreatitis.
5,6 Further-
more, CA 19-9 is not expressed at all by some pancreatic
tumors, and in other tumors, it is often not detectable until
pancreatic cancer is at a late and incurable stage.
7 Other
potential biomarkers such as carcinoembryonic antigen (CEA),
peanut agglutinin (PNA)-binding glycoproteins,
8 hTert (telom-
erase catalytic subunit),
9 and matrix metalloproteinase-2 (MMP-
2)
10 also lack clinical efﬁcacy. This situation has stimulated our
search for biomarkers that can be used for the early detection
of pancreatic cancer.
11
Despite signiﬁcant advances in proteomic methods and
instrumentation, discovery of circulating disease biomarkers
remains extremely challenging. We have developed a novel
approach for identifying biomarkers of pancreatic cancer in
human serum. The approach speciﬁcally addresses three of the
major obstacles in biomarker discovery.
The ﬁrst major obstacle is the accurate quantitation of large
numbers of proteins. The difﬁculty of accurate protein quan-
titation is compounded by nonspeciﬁc losses suffered during
extensive sample processing. For example, although immu-
noafﬁnity puriﬁcation removes the major abundant serum
proteins, signiﬁcant losses of low abundant proteins bound to
the high abundant proteins can occur.
12 Therefore, a stable
isotope labeled proteome (SILAP) standard added to serum
samples prior to immunopuriﬁcation can act as a carrier for
the low abundance proteins, controlling for and minimizing
the possibility of such losses.
13,14 The SILAP standard can also
control for and help to prevent losses that can occur throughout
the extensive workup procedure and LC-MS analysis, such as
the nonspeciﬁc binding of peptides to glassware and surfaces.
15
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standard, the corresponding unlabeled serum protein can be
quantiﬁed, if present. Absence of the unlabeled serum protein
when the labeled protein is identiﬁed confers increased
conﬁdence that the protein is truly absent in the serum sample,
as opposed to simply absent from the analysis due to sampling
error, ion suppression or nonspeciﬁc loss.
The second major obstacle is the identiﬁcation and charac-
terization of biologically relevant proteins in serum. In unbiased
shotgun analyses of serum samples, many of the proteins found
to be differentially expressed are abundant serum proteins or
nonspeciﬁc acute phase proteins, and not proteins related to
the disease process. By using a SILAP standard derived from
the secreted proteome of the CAPAN-2 pancreatic cancer cell
line, low abundance and biologically relevant biomarker can-
didates can be identiﬁed and relatively quantitated. These
proteins are generally present at much lower concentrations
in serum than in the secreted CAPAN-2 proteome, making their
quantitation and identiﬁcation difﬁcult without the use of a
SILAP standard.
The third obstacle remains the extraordinary complexity of
proteins present in human serum. In standard 2D-LC-MS/MS
protocols, proteins are fractionated after trypsin digestion.
Human serum contains proteins that are present over a wide
dynamic range,
16,17 so peptides from abundant proteins can
become widely distributed, interfering with identiﬁcation of
lower abundance proteins in many of the fractions collected.
One successful approach to improving the number of low
abundance proteins identiﬁed has been to perform increasing
numbers of orthogonal separation steps after tryptic digestion,
either serially or in parallel. Some examples include 1D gel-
electrophoresis,
18 IEF,
19 N-linked glycopeptide enrichment,
20
and cysteinyl peptide enrichment.
20 Immunoafﬁnity removal
of abundant proteins
21 has also proved to be a robust and
reproducible method for studying lower abundance proteins
in serum.
Fewer methods have been developed to successfully inte-
grate separation methods at the intact protein level with 2D-
LC-MS/MS. IEF of intact proteins is one of the most common
methods for separating complex protein mixtures. Historically,
this has been performed as the ﬁrst dimension of 2D gel
electrophoresis. Few studies have been reported, however,
demonstrating how this technique can be leveraged for sample
separation prior to 2D-LC-MS/MS. One study using liquid
phase IEF prior to trypsin digestion and reversed-phase 1D-
LC-MS/MS suggested the feasibility of this approach.
22 A similar
approach was taken to study plasma and amniotic ﬂuid.
23 In
this study, a proprietary IEF apparatus was used, prior to 1D-
LC-MS/MS. However, only 73 and 69 proteins were identiﬁed
in the respective samples. The power of IEF was suggested by
a more comprehensive study, which included solution IEF
followed by 1D-gel electrophoresis and LC-MS/MS, and was
able to identify over 2000 serum proteins.
24 With the develop-
ment of modern immobilized pH gradient (IPG) strips, the
reproducibility and resolution of IEF separation has been
signiﬁcantly improved. IPG strip capacity provides another
major advantage over other procedures, as up to 3 mg of
protein can be readily loaded on an 18 cm strip.
25 In the current
study, we have developed a method combining the use of a
SILAP standard with immunoafﬁnity removal of abundant
proteins and IEF-2D-LC-MS/MS analysis to identify a large
number of pancreatic cancer associated biomarkers.
Experimental Procedures
General Workﬂow. The workﬂow for sample processing is
presented in Figure 1. Equal amounts of a SILAP standard were
added to human serum samples, which were then subjected
to immunopuriﬁcation in order to remove high abundance
proteins. Serum samples were then fractionated by IEF; the
proteins were harvested, and digested with trypsin. Resulting
tryptic peptides were then fractionated by strong cation
exchange (SCX) chromatography and analyzed by reversed
phase 2D-LC-MS/MS.
Preparation of a SILAP Standard. Human caucasian, pan-
creas, adenocarcinoma (CAPAN-2) cells were obtained from the
Cell Culture Core of the University of Pennsylvania Center for
Molecular Studies in Digestive and Liver Diseases. The cells
were passaged at least ﬁve times using SILAC-based methodol-
ogy.
26 SILAC was developed as a simple and accurate approach
for MS-based quantitative proteomics. The method relies on
the incorporation of amino acids with substituted stable
isotopic nuclei, commonly 13C and 15N. In SILAC, cells are
grown in culture media that contains a stable isotope form of
a particular amino acid, commonly L-leucine or L-lysine. As
these are essential amino acids, cells incorporate labeled amino
acids into all newly synthesized proteins. Thus, with each cell
doubling the cell population replaces at least half of the original
form of the amino acid, eventually incorporating almost 100%
of the labeled amino acid. The SILAP standard and unlabeled
proteins from tissue or serum can then be combined and
processed together. When tryptic peptides are analyzed by LC-
MS, peptides from the labeled and unlabeled samples will differ
by a predictable number of mass to charge (m/z) units. The
ratio of peak intensities between the labeled and unlabeled
peptides then accurately reﬂects relative protein levels. This
differs signiﬁcantly from the original use of SILAC, which used
a single passage of isotopically labeled cells as the experimental
model and the unlabeled cells as a control. Brieﬂy, CAPAN-2
cells were grown to conﬂuence in DME/F12 media (Sigma, St.
Louis, MO) containing [13C6,15N1] leucine and [13C6,15N2] lysine
(Cambridge Isotopes, Cambridge, MA) and 10% dialyzed FBS
Figure 1. General workﬂow for processing of serum samples.
Pooled serum from pancreatic cancer patients or controls is
mixed with SILAC labeled conditioned media from CAPAN-2
cells. Abundant proteins are removed by immunoafﬁnity deple-
tion. Samples were separated by IEF. IPG strips were then cut
into pieces and digested with trypsin. Tryptic peptides were
separated by strong cation exchange, then analyzed by reversed-
phase LC-MS/MS.
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proteins as described previously.
27,28 Cells were subsequently
grown in serum-free media supplemented with insulin, trans-
ferrin and selenium (Sigma, St. Louis, MO). Conditioned media
was collected every 2 days, pooled, ﬁltered and aliquoted. The
SILAP standard was isolated by concentrating 45 mL (2 mg total
protein) of the SILAC conditioned media using 5000 MW cutoff
spin-ﬁlters (Millipore, Billerica, MA).
Characterization of Proteins in the SILAP Standard from
CAPAN-2 Cells. Proteins were incubated in boiling water for 5
min, reduced in 5 mM dithiothreitol (DTT) for1ha t6 0°C,
and alkylated with 15 mM iodoacetamide (IAA) for 30 min at
room temperature in the dark. Tryptic peptides were obtained
by digestion with sequencing grade trypsin (Promega, Madison,
WI) (1:50 w/w) overnight at 37 °C. Proteins were characterized
by standard 2D-LC-MS/MS analysis of the tryptic peptides as
described below. There was <0.5% of individual identiﬁed
unlabeled proteins in the SILAP standard.
Preparation of Serum Samples for IEF-2D-LC-MS/MS
Analysis. Two pooled serum samples were created, one con-
sisting of sera from 6 patients with known, early pancreatic
cancer, the other from 6 patients with benign pancreatic disease
(Table 1). All serum samples analyzed for this study were
collected from patients with suspected, resectable pancreatic
cancer or other pancreaticobiliary disease prior to surgical
resection. Disease status was subsequently conﬁrmed based
on operative and surgical pathological reports. One mg of the
SILAP standard was mixed with 300 µL of each pooled serum
sample (∼20 mg of serum protein). Each sample was processed
using an immunoafﬁnity column (Beckman-Coulter Pro-
teomeLab IgY-12 LC2 column, Fullerton, CA), which depletes
the 12 most abundant plasma proteins: albumin, IgG, trans-
ferrin, ﬁbrinogen, IgA, R2-macroglobulin, IgM, R1-antitrypsin,
haptoglobin, R1-acid glycoprotein, apolipoprotein A-I and
apolipoprotein A-II. The immunoafﬁnity column was attached
to an Hitachi EZChrome Elite HPLC. The immunoafﬁnity
column used for these experiments removed approximately
95% of the protein from normal, human serum samples as
determined by measuring serum protein concentration before
processing, and protein concentration of the ﬂow-through
fraction. As expected, only a negligible amount of protein is
lost from SILAP standard samples processed alone using this
immunoafﬁnity column. After processing, we estimate each
sample contained a mixture of approximately 1 mg of internal
standard and 1 mg of depleted serum protein.
Protein Separation by IEF. Protein concentrations were
determined by Coomassie Protein Assay (Pierce Scientiﬁc,
Milwaukee, WI). Two micrograms of each protein sample was
precipitated using a standard methanol/chloroform protocol,
then resuspended in 0.5% IPG buffer and DeStreak Rehydration
Solution (GE/Amersham Biosciences, Piscataway, NJ), a com-
mercially available, proprietary solution developed to prevent
nonspeciﬁc oxidation and streaking, resulting in improved
reproducibility. Isoelectric focusing of protein samples was
performed using 18 cm 3-10 NL IPG strips (GE/Amersham
Biosciences, Piscataway, NJ). The plastic backing was left in
place during processing to facilitate handling. Each strip was
cut into nine 2 cm pieces. Each piece was washed with 5%,
then 1% trichloroacetic acid (TCA), dehydrated with 90%
acetonitrile and allowed to air-dry. The approximate pI range
of each of these IPG pieces was estimated as follows from
information provided by the manufacturer: piece 1 (pI 3.0-4.0),
piece 2 (pI 4.0-5.0), piece 3 (pI 5.0-5.4), piece 4 (pI 5.4-5.8),
piece 5 (pI 5.8-6.0), piece 6 (pI 6.0-6 . 4 ) ,p i e c e7( p I 6.4-
7.6), piece 8 pI (7.6-9.0) and piece 9 (pI 9.0-10.0). Overnight
in-strip digestion was performed for each of the 2 cm pieces
using sequencing grade trypsin (Promega) diluted in 50 mM
ammonium bicarbonate at 37 °C. The supernatant was re-
moved and saved. Peptide extraction was performed by adding
1% triﬂuoroacetic acid/50% acetonitrile, and sonicating for 15
min. Extracted peptides were combined with the previously
removed supernatant and concentrated by lyophilization.
Separation of Peptides by SCX Chromatography. The pH
of each sample was lowered to 3 with 1% formic acid. An equal
volume of SCX mobile phase A (10 mM ammonium formate,
25% acetonitrile, pH 3) was added to each sample. SCX
chromatography was performed on a PolySulfethy A column
(100 mm × 2.3 mm, 5 µm 300 Å, PolyLC) attached to an 1100
Series HPLC (Agilent, Santa Clara, CA). Samples were loaded
for 5 min with mobile phase A, followed by a linear gradient
for 30 min to 100% mobile phase B (500 mM ammonium
formate, 25% acetonitrile, pH 6.8). Thirty-ﬁve 2 min fractions
were collected, pooled into 10-13 fractions, lyophilized, and
stored at - 80 °C awaiting further analysis. A total of 104
fractions from each of the pancreatic cancer serum and
pancreatic control serum samples were generated for analysis
by reversed phase LC-MS/MS. For characterization of the
CAPAN-2 secreted proteome, 18 pooled fractions were prepared
by SCX chromatography for analysis by reversed phase LC-MS/
MS.
Reversed-Phase Capillary LC-MS/MS Analyses. Lyophilized
peptides were reconstituted with 5% aqueous acetonitrile
containing 0.1% formic acid for reversed phase separation. A
nanoﬂow high pressure capillary LC system (Eksigent, Dublin,
CA) coupled on line to a linear ion trap Fourier transform ion
cyclotron resonance (FT-ICR) mass spectrometer (LTQ-FT,
Thermo Fisher, San Jose, CA) via an in-house-manufactured
nanoelectrospray ionization interface was used to analyze
peptide samples. The reversed-phase capillary column was
prepared by slurry-packing Alltech Prosphere C18-AQ, 5 µm,
100 Å into an 18 cm long, 360 µm outer diameter (od) × 75 µm
id fused silica capillary (New Objective, Woburn, MA) fritted
with a polymerized solution containing potassium silicate and
formamide. A trap column consisting of Alltech Prosphere C18,
10 µm, 300 Å slurry-packed intoa6c mlong, 360 µ od × 150
µm id fused silica capillary (New Objective, Woburn, MA) was
also used. Mobile phases were 0.1% formic acid in water (A)
and 0.1% formic acid in 100% acetonitrile (B). After loading 10
µL of peptides onto the column, the mobile phase was held at
95% A for 20 min. A linear gradient to 70% B was applied over
Table 1. Characteristics of Subjects Who Provide the 12
Serum Samples Used for the Pooled Samples and Initial
Validation
age gender disease
Cancer 50 M Pancreatic cancer, resectable
70 M Pancreatic cancer, resectable
66 M Pancreatic cancer, resectable
77 M Pancreatic cancer, resectable
68 F Pancreatic cancer, resectable
47 F Pancreatic cancer, resectable
Control 71 F Ampullary adenoma
49 F Pancreatic pseudocyst
80 M Chronic pancreatitis
67 F Pancreatic serous adenoma
47 F Chronic pancreatitis
29 F Chronic pancreatitis
Serum Protein Biomarkers of Pancreatic Cancer research articles
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mass spectrometer was operated in a data-dependent MS/MS
mode (m/z 300-2000) in which each full MS scan in the FT-
ICR was followed by 7 MS/MS scans in the ion trap. The seven
most intense precursor ions were dynamically selected in order
of highest to lowest intensity and then subjected to collision-
induced dissociation. The FT-ICR mass resolution was set at
50 000.
Protein Identiﬁcation. Raw data were submitted to Bioworks
Browser (Thermo Fisher, San Jose, CA) and batch searched
through SEQUEST against the NCBI RefSeq database of human
sequences (version updated 2/07). The database was indexed
using the following criteria: strict trypsin cleavage rules with
up to two internal cleavage sites; differential modiﬁcations of
methionine oxidation, carboxyamidomethlyation on cysteine,
[13C6,15N1]leucine and [13C6,15N2]lysine. All peptides shorter than
six amino acids were removed from the data set. The remaining
SEQUEST output ﬁles were further processed using the Trans-
Proteomic Pipeline (Institute for Systems Biology, Seattle, WA)
for analysis and validation of peptides and proteins using
PeptideProphet and ProteinProphet, respectively. PeptidePro-
phet peptide results where ﬁltered using a minimum peptide
probability of 0.3. ProteinProphet protein results were ﬁltered
using a minimum probability of 0.5. All proteins identiﬁed by
a single unique peptide were eliminated. XPRESS software was
originally developed for isotope coded afﬁnity tag (ICAT)
labeling experiments,
29 but which is equally applicable to other
differential labeling approaches such as SILAC. Starting with
an MS/MS spectra, either unlabeled or SILAC labeled, the
program reconstructs reverse phase elution proﬁles for both
the SILAC labeled and unlabeled precursor ions. Relative
quantitation of light and heavy peptides was performed using
XPRESS (also from the Trans-Proteomic Pipeline) with a parent
mass tolerance of 0.2 mass units and mass differences of
7.027630 mass units on leucine and 7.93217 lysine, correspond-
ing to [13C6,15N1]leucine and [13C6,15N2]lysine. The elution areas
of the labeled and unlabeled precursor ions are determined
and a ratio is generated. Manual validation by extracted ion
monitoring was performed on differentially expressed peptides.
Bioinformatics. For identifying pathways to which proteins
belong, the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database was used as a pathway reference.
30 In this database,
biological pathways have been curated manually and are
constantly updated. GenBank Geninfo Identiﬁer (GI) accession
numbers from proteins identiﬁed were used as a query to the
Protein Information Resource (PIR) database (http://pir.geor-
getown.edu). All human proteins corresponding to each GI
accession number were extracted. A majority of the GI acces-
sion numbers produced multiple proteins. Individual proteins
were then used as a query to the UniProt database to extract
the corresponding KEGG identﬁcations (IDs).
31 These conver-
sions were performed to compensate for any errors during the
assignment of KEGG IDs to GI accession numbers, thereby
providing more accurate results. Individual KEGG IDs were
searched against each pathway across the entire KEGG pathway
database speciﬁc to the species Homo sapiens. As is typical of
such analyses, not all GI accession numbers can be classiﬁed
into functional pathways. Many GI accession numbers are
implicated in multiple pathways. Some pathways such as cell
communication and cell motility have considerable overlapping
GI constituents. In a complementary analysis, Gene Ontology
(GO) classiﬁcations were performed using the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
Functional Annotation Tool (http://david.abcc.ncifcrf.gov) against
GI accession numbers identiﬁed in the CAPAN-2 secreted
proteome and in our human serum analyses.
Immunohistochemical Validation. Western blot analyses
were performed to conﬁrm presence of candidate proteins in
CAPAN-2 secreted proteome, pooled cancer and control serum.
Mouse monoclonal antibody to human matrix metalloprotein-
ase-7 (MMP-7), goat polyclonal antibody to human 14-3-3 zeta
(R&D Systems, Minneapolis, MN) and mouse monoclonal
antibody to human cytokeratin 18 (CK18) (Abcam, Cambridge,
MA) were purchased. Pooled serum proteins (15 µg)) from both
the pancreatic cancer and control cohorts used during the
discovery phase were diluted in LDS sample buffer (Invitrogen,
Carlsbad, CA). Samples were incubated at 60 °C for 10 min,
and separated on 4-12% Bis-Tris gels (NuPAGE Novex gels,
Invitrogen, Carlsbad, CA). A SeeBlue Plus2 (Invitrogen, Carls-
bad, CA) protein standard was used to estimate molecular
weights. Samples were then transferred to nitrocellulose mem-
brane (Invitrogen, Carlsbad, CA) and incubated with individual
primary antibodies diluted 1:500 for2ha troom temperature.
Membranes were then incubated for 45 min with the appropri-
ate secondary horseradish peroxidase-conjugated antibody
(Sigma, St. Louis, MO) diluted 1:5000. Protein bands were then
visualized by incubating membranes with ECL Plus detecting
reagents (Amersham Biosciences, Piscataway, NJ). Serum and
SILAP standard levels of MMP-7, intercellular adhesion mol-
ecule 1 (ICAM-1) and basal cell adhesion molecule (BCAM)
were measured by enzyme-linked immunosorbent assay (ELISA).
MMP-7 (R&D Systems, Minneapolis, MN), ICAM-1 (US Biologi-
cal, Swampscott, MA) and BCAM (R&D Systems, Minneapolis,
MN) ELISA kits were purchased and used according to manu-
facturer’s instructions.
Results
Characterization of Proteins Secreted by CAPAN-2 Cells.
A total of 666 proteins in 442 protein groups were identiﬁed in
the CAPAN-2 secreted proteome (Supplemental Table 1, Sup-
porting Information). To assess biological relevance, we com-
pared proteins secreted by the CAPAN-2 cell line to proteins
found to be up-regulated in pancreatic tumors.
32 Twenty-seven
of the 90 proteins previously identiﬁed as up-regulated in
pancreatic tumors were also found in the CAPAN-2 secreted
proteome. Gene Ontology (GO) functional annotation analysis
could be performed on 368 of the 666 proteins from the
CAPAN-2 secreted proteome. Forty-four of 367 proteins ana-
lyzed were classiﬁed as localizing to the extracellular region,
and 36 of these proteins were also classiﬁed as secreted.
Functional pathway analysis could be performed on 227 of the
666 proteins (Supplemental Table 2, Supporting Information).
Proteins from key biological pathways such as cell-cell com-
munication, proteasome, MAP kinase, Wnt signaling, focal
adhesion, leukocyte transendothelial migration, insulin signal-
ing and actin cytoskeleton were identiﬁed.
Proteins Characterized in Serum Samples. A total of 788
unique proteins from 568 functional protein groups were
identiﬁed in control serum samples by stable isotope dilution
IEF-2D-LC/MS/MS (Supplemental Table 3, Supporting Infor-
mation). A total of 778 unique proteins from 529 functional
groups were identiﬁed in the pancreatic cancer serum samples
(Supplemental Table 4, Supporting Information). Together, a
total of 1065 serum proteins were identiﬁed in both samples;
501 (47%) of these proteins were identiﬁed in both samples,
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sample, and 287 proteins identiﬁed only in the control sample
(Figure 2).
Differential Secretion of Proteins into Pancreatic Cancer
Serum. For each protein, an XPRESS ratio was generated
representing the ratio of the unlabeled protein from the serum
to the labeled protein from the SILAP standard. Proteins present
in only the unlabeled form, and therefore absent in our SILAP
standard, were excluded from further analysis. As the same
amount of the SILAP standard was added to both pooled cancer
and control serum samples, cancer and control XPRESS ratios
could be compared for each protein. For 121 proteins, the
relative amount in the cancer serum exceeded that in the
control serum by 1.5-fold or more (Table 2). Two of these
proteins, transgelin 2 and cathepsin D, were previously identi-
ﬁed to be up-regulated in pancreatic tumors.
32 Manual review
of extracted ion current spectra was performed to conﬁrm
differential XPRESS ratios. Examples of extracted ion current
spectra are presented (Figure 3).
Western Blot Analyses. The protein ratios generated by
XPRESS, indicated that levels of many candidate biomarkers
were present at much higher levels in the SILAP standard than
in either the cancer or control serum. For example, for MMP-
7, the serum to SILAP standard ratio was 1:180.5 in the cancer
sample and 1:290 in the control sample. For 14-3-3 zeta, the
ratios were 1:95.0 and 1:213.4 (cancer and control, respectively).
For CK18, the ratios were 1:127.0 and 1:223.1 (cancer and
control, respectively). Western blot analysis for these three
proteins conﬁrmed this observation. MMP-7 and 14-3-3 zeta
were clearly detected in the SILAP standard, but not detected
in either the pooled cancer or control serum samples (Figure
4). The Western blot results for CK18 demonstrated two bands
at approximately 21 kD and 26 kD in the SILAP standard,
whereas the predicted molecular weight for CK18 approximates
to 47 kD. During apoptosis, CK18 is known to be cleaved by
caspase 3 and caspase 6 at Asp398, then Asp237, resulting in a
21 and 26 kD fragment.
33,34 Neither cleavage product was
observed in the cancer and control serum samples. A faint band
was present in both serum samples at approximately 47 kD,
which might have arisen from the intact CK18 protein. How-
ever, the intact protein was not detected in the SILAP standard.
Conﬁrmation of Differential Protein Secretion into Serum
by ELISA. For improved sensitivity and to allow for quantita-
tion, enzyme-linked immunosorbent assays (ELISA) were per-
formed. ELISA kits were available for three candidate protein
biomarkers: MMP-7, ICAM-1 and BCAM. Protein concentra-
tions were measured in the SILAP standard and in the
individual cancer and control serum samples. MMP-7 concen-
trations in the SILAP standard was 724.93 ng/mL. Because there
was no signiﬁcant difference in MMP-7 concentration between
pooled cancer and control serum samples (data not shown),
further validation was not pursued. Serum concentrations of
MMP-7 averaged 19.962 ng/mL. Both ICAM-1 and BCAM
concentrations were signiﬁcantly elevated in the individual
cancer serum samples compared with control samples (Figure
5 and Figure 6, respectively). These differences conﬁrmed the
ﬁndings of our SILAP standard discovery study. ICAM-1 and
BCAM concentrations were measured in the SILAP standard,
as well. BCAM concentration was 2904 pg/mL, while the
ICAM-1 concentration was 17 ng/mL. It is noteworthy the
concentrations of BCAM and MMP-7 were signiﬁcantly greater
in the SILAP standard than in human serum, whereas ICAM-1
was found at a much lower concentration in the SILAP
standard.
Independent Validation of Biomarker Candidates. On the
basis of the ELISA results, ICAM-1 and BCAM were chosen for
further validation in an independent set of human serum
samples. Ten patients with pancreatic cancer and 10 controls
(Table 3) were analyzed. Similar to the patients whose sera were
used in the discovery phase, these 20 serum samples were
drawn from patients with suspected, resectable pancreatic
cancer or other pancreaticobiliary disease prior to surgical
resection. The nature of their disease was conﬁrmed based on
operative and surgical pathological reports. ICAM-1 and BCAM
levels were signiﬁcantly elevated in these cancer samples when
compared with controls (Figure 7 and Figure 8, respectively).
For both ICAM-1 and BCAM, regression analysis was performed
to determine if patient age could account for differences in
relative protein levels seen across all serum samples (Table 4).
No signiﬁcant association was found. Regression analysis was
also performed to determine whether any correlation between
BCAM and ICAM-1 levels (Table 4). No signiﬁcant relationship
was found when all samples were analyzed together, or when
cancer and control samples were analyzed separately. Student’s
t-tests were performed to determine if levels of ICAM-1 or
BCAM were associated with patient gender or tumor resect-
ability (Table 5). No association was found.
Discussion
SILAC has become an important tool for proteomic studies
in vitro; this study has demonstrated that SILAC can be used
to prepare a SILAP standard, which can then be employed to
quantify pancreatic cancer speciﬁc proteomic changes in
human serum (Figure 1). Although we have targeted pancreatic
cancer-speciﬁc proteins, the SILAP standard can be tailored
to focus on any malignancy or disease for which a reasonable
cell line model exists. Combining this SILAP standard approach
with extensive, multidimensional LC-MS/MS, a large group of
pancreatic cancer-speciﬁc proteins was identiﬁed (Figure 2)
and shown to be differentially secreted into human serum
(Table 2). This made it possible to identify differentially secreted
proteins (Figure 4) that were below the limits of sensitivity of
Western blot analyses (Figure 4).
The SILAP standard approach offers several advantages to
the standard shotgun approach. As with any method integrating
a labeled internal standard, the method allows for relative
quantitation of the corresponding unlabeled serum proteins,
while controlling for nonspeciﬁc losses during extensive sample
processing. Limiting the analysis to serum proteins that were
Figure 2. Venn diagram of proteins identiﬁed from cancer and
control serum samples. Equal amounts of the SILAP standard
were added to each serum sample.
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entry no. protein name cancer to control ratio entry no. protein name cancer to control ratio
1 RP26, ceramide kinase-like 19980.00 62 GANAB, alpha glucosidase II
alpha subunit
5.13
2 ORP150 or HYOU1, oxygen
regulated protein precursor
1012.33 63 PPIA, peptidylprolyl
isomerase A
5.00
3 FLNA, ﬁlamin A, alpha 623.55 64 SHMT2, serine
hydroxymethyltransferase 2
(mitochondrial)
5.00
4 UBE2L3,
ubiquitin-conjugating
enzyme E2L 3 isoform 1
332.22 65 DDT, D-dopachrome
tautomerase
4.99
5 LMO7, LIM domain only 7 268.20 66 Eef1a1, eukaryotic
translation elongation
factor 1 alpha 1
4.49
6 FILIP, ﬁlamin A interacting
protein 1
221.67 67 peroxiredoxin 6 4.47
7 STXBP2 or Unc18-2,
syntaxin binding protein 2
215.77 68 catalase 4.31
8 CENPE, centromere protein
E
204.00 69 S100P or MIG9, S100
calcium binding protein P
4.16
9 PTPRJ, protein tyrosine
phosphatase, receptor type,
J precursor
136.00 70 PREDICTED: similar to
Phosphoglycerate mutase 1
(Phosphoglycerate mutase
isozyme B) (PGAM-B)
4.07
10 ARHGEF15 or GEF 15, Rho
guanine exchange factor 15
121.67 71 hypothetical protein
LOC345651
4.00
11 PREDICTED: similar to
Elongation factor 1-gamma
(EF-1-gamma) (eEF-1B
gamma), eukaryotic
translation elongation
factor 1 gamma
120.94 72 GTP-binding protein PTD004
isoform 1
3.83
12 CLSTN1, calsyntenin 1 103.45 73 SMAP1L, stromal
membrane-associated
protein 1-like
3.65
13 DAK, dihydroxyacetone
kinase 2
95.57 74 14-3-3 theta, tyrosine
3\tryptophan 5
-monooxygenase activation
protein, theta polypeptide
3.65
14 ARPC2, Actin related protein
2\3 complex subunit 2
88.20 75 AXL, AXL receptor tyrosine
kinase
3.63
15 MYH9, myosin, heavy
polypeptide 9, nonmuscle
63.26 76 ACY1, aminoacylase 1 3.50
16 PDXK, pyridoxal kinase 62.54 77 carbonic anhydrase I 3.43
17 ON or SPARC, secreted
protein, acidic,
cysteine-rich (osteonectin)
56.72 78 PLCL2, phospholipase
C-like 2
3.29
18 RKIP, prostatic binding
protein
55.82 79 GPR126, G protein-coupled
receptor 126 alpha 1, G
protein-coupled receptor
126 beta 1, G
protein-coupled receptor
126 alpha 2, G
protein-coupled receptor
126 beta 2
3.20
19 AST, aspartate
aminotransferase 1
55.00 80 3‘(2’), 5′-bisphosphate
nucleotidase 1
3.19
20 cardiac muscle alpha Actin 1
proprotein
36.22 81 PSME1, proteasome
activator subunit 1
3.15
21 PKP2, plakophilin 2 26.33 82 SERPINB1, serine (or
cysteine) proteinase
inhibitor, clade B
(ovalbumin), member 1
3.00
22 CANT1, calcium activated
nucleotidase 1
26.00 83 GSTO1,
glutathione-S-transferase
omega 1
3.00
23 S100A4, S100
calcium-binding protein A4
25.88 84 moesin 3.00
research articles Yu et al.
1570 Journal of Proteome Research • Vol. 8, No. 3, 2009Table 2. Continued
entry no. protein name cancer to control ratio entry no. protein name cancer to control ratio
24 HNRPD or AUF1,
heterogeneous nuclear
ribonucleoprotein D
24.49 85 cathepsin C isoform a
preproprotein
2.99
25 RCN1, reticulocalbin 1
precursor
23.62 86 ADP-ribosylation factor 1 2.98
26 ARHGDIA, Rho GDP
dissociation inhibitor (GDI)
alpha
23.30 87 TPI1, triosephosphate
isomerase 1
2.96
27 B-CAM, basal cell adhesion
molecule precursor
23.30 88 ACTN1, actinin, alpha 1 2.80
28 myosin regulatory light
chain MRCL3, myosin
regulatory light chain
MRCL2
21.82 89 NUDT5, nudix-type motif 5 2.79
29 PLAP, placental alkaline
phosphatase preproprotein
20.33 90 ERO1L, ERO1-like 2.78
30 LHPP, phospholysine
phosphohistidine inorganic
pyrophosphate
phosphatase
19.92 91 uPA, urokinase plasminogen
activator preproprotein
2.64
31 RRBP1, ribosome binding
protein 1
19.67 92 P4HB, prolyl 4-hydroxylase,
beta subunit precursor
2.63
32 CAPZA1, F-Actin capping
protein alpha-1 subunit
19.42 93 hypothetical protein
LOC57653
2.59
33 UBE2N,
ubiquitin-conjugating
enzyme E2N
18.30 94 MYEF2, myelin gene
expression factor 2
2.56
34 EFHD2, EF hand domain
family, member D2
16.82 95 RyR3, ryanodine receptor 3 2.56
35 Chd7, chromodomain
helicase DNA binding
protein 7
16.75 96 ras homologue gene family,
member A
2.51
36 GGH, gamma-glutamyl
hydrolase precursor
16.03 97 ENO1, enolase 1 2.50
37 CAPZB, F-Actin capping
protein beta subunit
15.27 98 DENN\MADD domain
containing 2C
2.50
38 intercellular adhesion
molecule 1 precursor
14.00 99 EPS8L1, epidermal growth
factor receptor pathway
substrate 8-like protein 1
isoform a
2.50
39 CLIC1, chloride intracellular
channel 1
13.84 100 proteasome alpha 5 subunit 2.48
40 DJ-1 protein 13.19 101 BAIAP2, BAI1-associated
protein 2
2.45
41 TPP1, tripeptidyl-peptidase I
preproprotein
12.51 102 cathepsin D preproprotein 2.44
42 SDCBP2, syndecan binding
protein 2
12.48 103 Maspin (SERPINB5), serine
(or cysteine) proteinase
inhibitor, clade B
(ovalbumin), member 5
2.42
43 major histocompatibility
complex, class I, B,
PREDICTED: similar to
HLA class I
histocompatibility antigen,
B-18 alpha chain precursor
(MHC class I antigen B*18)
12.31 104 PGLS,
6-phosphogluconolactonase
2.35
44 Sumo 2 or Sumo 3,
PREDICTED: similar to
SMT3 suppressor of mif
two 3 homologue 2, small
ubiquitin-like modiﬁer
protein 3
12.13 105 14-3-3zeta, tyrosine
3\tryptophan 5
-monooxygenase activation
protein, zeta polypeptide,
tyrosine 3\tryptophan 5
-monooxygenase activation
protein, zeta polypeptide
2.25
45 BLVRB, biliverdin reductase
B (ﬂavin reductase
(NADPH))
10.50 106 Chaperonin 2.21
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out acute phase proteins and other abundant serum proteins,
while simultaneously focusing on proteins with biological
relevance to pancreatic cancer. Absolute quantitation by ELISA
for ICAM-1 and BCAM conﬁrmed the differences uncovered
by the SILAP standard method, and demonstrates the sensitivity
gain afforded by this method (Figures 5–8). For example, BCAM
was present in control serum samples at the 100-200 pg/mL
range (Figures 6 and 8).
The separation workﬂow integrates immunoafﬁnity removal
of the twelve most abundant serum proteins and IEF at the
intact protein level prior to standard 2D–LC (Figure 1). Imple-
mentation of IEF is relatively straightforward, as all equipment
and consumables for IEF are commercially available. Indeed,
IEF is widely used as the ﬁrst dimension of 2D gel electro-
phoresis. As part of multidimensional LC-MS/MS, IEF is an
attractive, orthogonal fractionation option. Along with SEC and
anion exchange, it represents one of the few readily available
options for sample fractionation at the intact protein level. As
more dimensions of fractionation are integrated, several tradeoffs
emerge. For example, extensive fractionation requires a greater
amount of starting material. One advantage of IEF is the high
sample capacity of IPG strips. Although, in this study, only 2D-
LC was performed after IEF, it is certainly feasible to integrate
more dimensions of fractionation in order to obtain a more
comprehensive analysis. As more processing steps are added,
the nonspeciﬁc loss of proteins increases. This is particularly
important for low abundance proteins. Another, more difﬁcult
to address tradeoff is the exponential increase in MS data
acquisition time that results from increased fractionation. In
this study, the amount time required for data acquisition from
a sample processed by IEF-2D-LC-MS/MS was approximately
18 days. Replicate analysis becomes impractical given these
long analysis times. This problem only deepens as more layers
of fractionation are added. With extensive fractionation, para-
doxically, the redundant analysis of abundant proteins in-
creases. Some of the most abundant peptides are sequenced
hundreds of times. Development of algorithms and methods
for the dynamic and static exclusion of these abundant peptides
could improve the number of low abundance proteins identiﬁed.
The pancreatic cancer focused approach to biomarker
discovery allows for the discovery of biologically relevant
candidates. A number of proteins found in this study to be
overexpressed in pancreatic cancer serum have been implicated
in essential processes responsible for tumor growth and spread.
For example, degradation of the extracellular matrix (ECM) is
a key biological process that promotes the invasion of pancre-
atic tumors into their surrounding tissue. The cysteine protease
cathepsin C and the aspartic protease cathepsin D have been
implicated in ECM degradation, facilitating tumor growth,
Table 2. Continued
entry no. protein name cancer to control ratio entry no. protein name cancer to control ratio
46 zinc ﬁnger protein 704 10.00 107 heme binding protein 2 2.16
47 S100A16, S100 calcium
binding protein A16
9.10 108 SH3BGRL3, SH3 domain
binding glutamic acid-rich
protein like 3
2.13
48 SEMA7A, semaphorin 7A 8.49 109 keratin 8 2.02
49 CHMP2B, chromatin
modifying protein 2B
8.49 110 vinculin isoform VCL,
vinculin isoform meta-VCL
2.00
50 NSD1, nuclear receptor
binding SET domain
protein 1
7.67 111 collagen, type VI, alpha 1
precursor
1.96
51 myoglobin 7.15 112 podocalyxin-like precursor 1.88
52 STIP1,
stress-induced-phosphoprotein
1 (Hsp70\Hsp90-organizing
protein)
7.00 113 TCN1, transcobalamin I
precursor
1.85
53 IFI30 or IP-30, interferon,
gamma-inducible protein
30 preproprotein
7.00 114 BST2, bone marrow stromal
cell antigen 2
1.81
54 NME1-NME2 protein 6.74 115 keratin 18 1.76
55 ephrin receptor EphA2 6.68 116 HSPG2, heparan sulfate
proteoglycan 2
1.73
56 RNPEP, arginyl
aminopeptidase
(aminopeptidase B)
6.50 117 Ezrin, villin 2 1.69
57 DENN\MADD domain
containing 2A
6.13 118 cytosolic malate
dehydrogenase
1.65
58 TAL1 or TALDO1,
transaldolase 1
6.00 119 MMP-7, matrix
metalloproteinase 7
preproprotein
1.61
59 PVRL1 or CD111, poliovirus
receptor-related 1
(herpesvirus entry mediator
C; nectin)
5.64 120 TAGLN2, transgelin 2 1.57
60 APLP2, amyloid beta (A4)
precursor-like protein 2
5.50 121 cystatin M precursor 1.52
61 ARMET, arginine-rich,
mutated in early stage
tumors
5.18
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(uPA), a serine protease, has similarly been implicated in the
degradation of ECM. Cystatin M has been characterized as an
inhibitor of lysosomal cysteine proteases, thereby acting as a
tumor suppressor by inhibiting the growth and migration of
tumor cells. While cystatin M expression in pancreatic cancer
is not well studied, a recent study reports cystatin M is
overexpressed in pancreatic tumors, and addition of functional
cystatin M to culture media promotes cell proliferation.
35
Another important pathway in carcinogenesis is apoptosis.
Paradoxically, apoptosis is often increased in malignant tumors,
usually accompanied by increased proliferation.
36 In breast
cancer, increased apoptosis has also been associated with a
worse prognosis.
36-38 CK18 is a member of the intermediate
ﬁlament system, and is expressed at high levels in epithelial
cells and malignancies. During apoptosis, CK18 is cleaved by
caspases and released into the extracellular compartment.
Presence of caspase cleaved CK18 has been shown to be a
reliable marker of apoptosis, while release of intact CK18
reﬂects necrosis.
39 Increased levels of caspase-cleaved CK18
have been measured in the serum of breast cancer patients
when compared with controls.
40
Angiogenesis is an important process for the growth and
metastasis of pancreatic tumors. Heparan sulfate proteoglycan
2 (perlecan) is an ECM protein closely associated with vascular
endothelia, and has been shown to play a key role in vascu-
logenesis. Modulation of cell-cell adherence also plays an
important role in cancer invasion. A number of proteins
important for the formation of adherens junctions, such as
Figure 3. LC-MS ion current proﬁles of tryptic peptides obtained
from pancreatic cancer and control serum proteins. Two pairs
of chromatograms are presented for each tryptic peptide. The
upper chromatogram is from the unlabeled peptide and the lower
chromatogram is from the SILAP-derived standard peptide. (A)
Syndecan binding protein 2 peptide R.RAEIKPGVR.E from pan-
creatic cancer serum. (B) Syndecan binding protein 2 peptide
R.RAEIKPGVR.E from control serum. (C) Biliverdin reductase B
peptide R.LQAVTDDHIR.M from pancreatic cancer serum. (D)
Biliverdin reductase B peptide R.LQAVTDDHIR.M from control
serum.
Figure 4. Western blot results for CK-18, 14-3-3 zeta and MMP-
7. Bands representing 14-3-3 zeta and MMP-7 are clearly
present in the SILAP standard, but not visible in either serum
samples. Two bands at approximately 21 and 26 kD, likely
representing speciﬁc caspase cleavage fragments of CK-18, are
visible in the SILAP standard but not in the serum samples. A
faint band at roughly 47 kD is present in both serum samples,
and may represent the intact CK18.
Figure 5. ICAM-1 concentrations in the six cancer and six control
serum samples studied. Mean ICAM-1 concentration in cancer
sera was signiﬁcantly greater than in controls.
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protein were found to be overexpressed in pancreatic cancer
serum. Inﬂammation and leukocyte recruitment, through a
number of proposed mechanisms, appear to play a key role in
tumor progression and evasion of the immune response.
ICAM-1 expressed on endothelial cells engages R1 2-integrin
expressed by passing neutrophils. Transendothelial migration
by leukocytes also is believed to occur via an ICAM-1 depend-
ent manner. The proteins ezrin, radixin and moesin (ERM) have
been hypothesized to act as linkers between ICAM-1 and
cytoskeletal proteins (such as actin and vimentin) providing
structural support as endothelial cells form channels to permit
transendothelial migration.
41 While ICAM-1 expression in
pancreatic tissue has been implicated in pancreatitis and
pancreatic cancer, measurement of ICAM-1 as a serum marker
of pancreatic cancer has not been previously described.
BCAM is a laminin receptor in the Ig superfamily. Little is
known about the normal role and distribution of this protein,
however, it appears to bind speciﬁcally to R5 chain containing
laminin proteins. While BCAM expression in pancreatic cancer
has not previously been described, overexpression in ovarian
cancer
42 and some cutaneous malignancies have been re-
ported.
43 Laminin R5 is widely expressed in basement mem-
branes, and therefore some have hypothesized that BCAM may
play a role during the process of tumor invasion.
44 Other
investigators have noted the sequence similarity between
BCAM and the melanoma antigen MUC18.
45 MUC18, an
Figure 6. BCAM concentrations in the six cancer and six control
serum samples studied. Mean BCAM concentration in cancer
sera was signiﬁcantly greater than in controls.
Table 3. Characteristics of Subjects Who Provided the 20
Serum Samples Used for Independent Validation of ICAM-1
and BCAM Levels
age gender disease
Cancer 69 M Pancreatic cancer, resectable
58 M Pancreatic cancer, unresectable
75 F Pancreatic cancer, resectable
74 F Pancreatic cancer, unresectable
41 F Pancreatic cancer, unresectable
72 F Pancreatic cancer, resectable
19 F Pancreatic cancer, resectable
78 M Pancreatic cancer, resectable
59 M Pancreatic cancer, resectable
73 M Pancreatic cancer, unresectable
Control 76 M Duodenal polyp
37 M Pancreatic pseudocyst
70 M Benign biliary stricture
37 F Mucinous cystic neoplasm, pancreas
66 M Macrocystic adenoma, pancreas
72 M Islet cell tumor
45 M Pancreatic pseudocyst
33 F Acinic cell cystadenoma, pancreas
56 F Mucinous cystic neoplasm, pancreas
64 F Mucinous cystic neoplasm, pancreas
Figure 7. ICAM-1 concentrations in ten cancer and ten control
serum samples from an independent cohort. Mean ICAM-1
concentration in cancer sera was signiﬁcantly greater than in
controls.
Figure 8. BCAM concentrations in ten cancer and ten control
serum samples from an independent cohort. Mean BCAM
concentration in cancer sera was signiﬁcantly greater than in
controls.
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role in cell-ECM interactions and may promote tumor invasion
and metastasis.
46
Conclusions
Sophisticated discovery strategies, like the one presented
here, are now identifying many low abundance protein biom-
arker candidates. Such an approach, however, is impractical
for replicate analysis, validation or for large scale clinical
application. Standard immunological validation, however, re-
mains challenging. High quality antibodies are often unavail-
able for proteins of interests, and development of ELISAs can
be time-consuming and difﬁcult. The SILAP standard strategy,
however, provides a logical way forward. Candidate peptides
for LC-multiple reaction monitoring (MRM)/MS analyses are
identiﬁed and characterized during the discovery phase. The
SILAP standard can then also be used for relative quantitation
by LC-MRM/MS, a strategy that is currently under active
validation. Absolute quantitation can also be performed, as
candidate peptides identiﬁed during the discovery phase can
then be synthesized as heavy isotope analogs and used as
internal standards for standard stable isotope dilution LC-
MRM/MS analyses. A recent study has shown that such an
approach is capable of accurately measuring plasma proteins
in the high pg range.
47 This approach will permit multiple
biomarker candidates to be analyzed simultaneously. Simul-
taneous monitoring of even a fraction of the 121 candidate
biomarkers discovered using our SILAP standard approach
would be a major step forward toward a test that could detect
pancreatic cancer at an early and curable stage.
Abbreviations: SILAP, stable isotope labeled proteome; MS/
MS, tandem mass spectrometry; SILAC, stable isotope labeling
by amino acids in cell culture; IEF, isoelectric focusing; 2D-
LC, two-dimensional liquid chromatography; IPG, immobilized
pH gradient; SCX, strong cation exchange; CAPAN-2, Human
Caucasian, pancreas, adenocarcinoma cells; KEGG, Kyoto
Encyclopedia of Genes and Genomes; GI, GenBank Geninfo
Identiﬁer; GO, Gene Ontology; MMP-7, matrix metalloprotein-
ase-7; CK18, cytokeratin 18; ICAM-1, intercellular adhesion
molecule 1; BCAM, basal cell adhesion molecule; ELISA,
enzyme-linked immunosorbent assay.
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